Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Active, not recruiting · Phase 1, Phase 2 · NCT05407441
Conditions: Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
At a glance
- Research payments reported, 2025
- $20,829
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 49
About the trial
- Sponsor
- Susan Chi, MD (with Bristol-Myers Squibb, Epizyme, Inc.)
- Tested
- Tazemetostat (drug), Nivolumab (drug), Ipilimumab (drug)
- Dates
- Started 2023-08-10; completion 2029-02-01
- Results posted
- Not yet
This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: * Tazemetostat (TAZVERIK) * Nivolumab (OPDIVO) * Ipilimumab (YERVOY)
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $20,829 in research payments for this study in 2025 (4 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $19,019
- Dana-Farber Cancer Institute $1,810
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.